Skip to main content
. 2022 May 12;66(3):312–323. doi: 10.20945/2359-3997000000478

Table 5. Characteristics of participants.

Clinical characteristics Baseline After intervention
Placebo Sitagliptin
Age (years) 58 ± 11
Men/Women, n (%) 9/7 (56/44)
BMI (kg/m2) 27 ± 2
BMI > 25.0 kg/m2, n (%) 14 (87)
Family history of T2DM, n (%) 11 (69)
Systolic arterial hypertension, n (%) 9 (56)
SAP (mmHg) 136 ± 26
DAP (mmHg) 77 ± 16
Total cholesterol (mg/dL)a 219 ± 52
LDL-cholesterol (mg/dL)a 133 ± 50
HDL-cholesterol (mg/dL)a,b 42 ± 13
VLDL-cholesterol (mg/dL)a 33 [27–45]
Triglycerides (mg/dL)a 165 [135–226]
HbA1c (%) (mmol/L)a 7.7 ± 1.2 (61 ± 0.1)
Glucose (mg/dL)a 164 ± 43 137 [125–191] 130 [109–163]*
Insulin (μIU/mL)a 20 ± 14 19 ± 14 15 ± 8
C-peptide (ng/mL)a 3.8 ± 1.8 3.8 ± 1.8 3.6 ± 1.6
GLP-1 (pg/mL)a 719 ± 179 688 ± 209 689 ± 205
Glucagon (pg/mL)a 73 [57–88] 70 ± 17 74 ± 24
NEFA (mmol/L)a 0.61 ± 0.19 0.61 ± 0.19 0.58 ± 0.16
HOMA-IR 4.8 [2.2-10.1] 4.7 [2.6-7.6]
QUICKI 0.30 ± 0.03 0.31 ± 0.03
Adipo-IR 9.9 [5.7-14.9] 8.8 [6.0-10.6]
Matsuda indexc 3 ± 2 3 ± 1.2
Insulinogenic indexc 0.3 [0.1-0.65] 0.56 [0.28-0.73]*

Values are presented as mean ± SD or median [interquartile range] or number (n) followed by the respective proportion (%). n = 16.

*

means p < 0.05 using paired Student t-test or Wilcoxon matched-pairs for symmetric and asymmetric data, respectively.

BMI: body mass index; T2DM: type 2 diabetes mellitus; SAP: systolic arterial pressure; DAP: diastolic arterial pressure; LDL: low-density lipoprotein; HDL, high-density lipoprotein; VLDL: very-low-density lipoprotein; HbA1c: haemoglobin A1c; GLP-1: glucagon-like peptide-1; NEFA: non-esterified fatty acids; HOMA: homeostasis model assessment of insulin resistance; QUICKI: quantitative insulin sensitivity check index; Adipo-IR: adipose tissue insulin resistance.

a

Under fasting.

b

No differences between man and women values.

c

Insulinogenic index and Matsuda index were obtained from the CHO meal test.